Manfred JÃ¼cker

List of Publications by Year
in descending order

42 papers	1,678 citations	304602 22 h-index	302012 39 g-index
42 all docs	42 docs citations	42 times ranked	2788 citing authors

#	Article	IF	Citations
1	Distinct functions of AKT isoforms in breast cancer: a comprehensive review. Cell Communication and Signaling, 2019, 17, 154.	2.7	192
2	PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer. Biochemical Pharmacology, 2020, 172, 113729.	2.0	174
3	The Role of mTOR Signaling as a Therapeutic Target in Cancer. International Journal of Molecular Sciences, 2021, 22, 1743.	1.8	128
4	Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Molecular Cancer, 2012, 11, 85.	7.9	97
5	COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer. Molecular Cancer, 2015, 14, 109.	7.9	89
6	Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects. Clinical Cancer Research, 2015, 21, 2388-2398.	3.2	88
7	Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity. EMBO Molecular Medicine, 2020, 12, e11908.	3.3	77
8	Distinct functional roles of Akt isoforms for proliferation, survival, migration and EGF-mediated signalling in lung cancer derived disseminated tumor cells. Cellular Signalling, 2011, 23, 1952-1960.	1.7	76
9	Combined targeting of AKT and mTOR using MKâ€2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma. International Journal of Cancer, 2013, 133, 2065-2076.	2.3	71
10	The Functional Role of Extracellular Matrix Proteins in Cancer. Cancers, 2022, 14, 238.	1.7	65
11	Downregulation of AKT3 Increases Migration and Metastasis in Triple Negative Breast Cancer Cells by Upregulating S100A4. PLoS ONE, 2016, 11, e0146370.	1.1	61
12	Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors. Investigational New Drugs, 2014, 32, 1144-1154.	1.2	50
13	Suppression of Early Hematogenous Dissemination of Human Breast Cancer Cells to Bone Marrow by Retinoic Acidâ€“Induced 2. Cancer Discovery, 2015, 5, 506-519.	7.7	45
14	Dual Targeting of Akt and mTORC1 Impairs Repair of DNA Double-Strand Breaks and Increases Radiation Sensitivity of Human Tumor Cells. PLoS ONE, 2016, 11, e0154745.	1.1	42
15	AKT3 regulates ErbB2, ErbB3 and estrogen receptor Î± expression and contributes to endocrine therapy resistance of ErbB2+ breast tumor cells from Balb-neuT mice. Cellular Signalling, 2014, 26, 1021-1029.	1.7	37
16	PTEN mediates the cross talk between breast and glial cells in brain metastases leading to rapid disease progression. Oncotarget, 2017, 8, 6155-6168.	0.8	35
17	Vertical Targeting of AKT and mTOR as Well as Dual Targeting of AKT and MEK Signaling Is Synergistic in Hepatocellular Carcinoma. Journal of Cancer, 2015, 6, 1195-1205.	1.2	34
18	Targeted PI3K/AKT-hyperactivation induces cell death in chronic lymphocytic leukemia. Nature Communications, 2021, 12, 3526.	5.8	34

#	Article	IF	Citations
19	Akt isoform specific effects in ovarian cancer progression. Oncotarget, 2016, 7, 74820-74833.	0.8	33
20	Leukemia-associated mutations in SHIP1 inhibit its enzymatic activity, interaction with the GM-CSF receptor and Grb2, and its ability to inactivate PI3K/AKT signaling. Cellular Signalling, 2012, 24, 2095-2101.	1.7	31
21	Combined inhibition of GLI and FLT3 signaling leads to effective anti-leukemic effects in human acute myeloid leukemia. Oncotarget, 2017, 8, 29187-29201.	0.8	28
22	High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors. Cells, 2020, 9, 2129.	1.8	26
23	The tumor suppressor SHIP1 colocalizes in nucleolar cavities with p53 and components of PML nuclear bodies. Nucleus, 2015, 6, 154-164.	0.6	24
24	The inositol 5-phosphatase SHIP1 is a nucleo-cytoplasmic shuttling protein and enzymatically active in cell nuclei. Cellular Signalling, 2012, 24, 621-628.	1.7	18
25	Circulating tumor cells as a promising target for individualized drug susceptibility tests in cancer therapy. Biochemical Pharmacology, 2021, 188, 114589.	2.0	18
26	Combined Targeting of AKT and mTOR Inhibits Proliferation of Human NF1-Associated Malignant Peripheral Nerve Sheath Tumour Cells In Vitro but not in a Xenograft Mouse Model In Vivo. International Journal of Molecular Sciences, 2020, 21, 1548.	1.8	15
27	Knockdown of AKT3 Activates HER2 and DDR Kinases in Bone-Seeking Breast Cancer Cells, Promotes Metastasis In Vivo and Attenuates the TGFÎ²/CTGF Axis. Cells, 2021, 10, 430.	1.8	14
28	An increase in the expression and total activity of endogenous p60c-Src in several factor-independent mutants of a human GM-CSF-dependent leukemia cell line (TF-1). Oncogene, 2003, 22, 7170-7180.	2.6	12
29	AKT in Bone Metastasis of Solid Tumors: A Comprehensive Review. Cancers, 2021, 13, 2287.	1.7	10
30	Combined Targeting of AKT and mTOR Synergistically Inhibits Formation of Primary Colorectal Carcinoma Tumouroids In Vitro: A 3D Tumour Model for Pre-therapeutic Drug Screening. Anticancer Research, 2021, 41, 2257-2275.	0.5	8
31	Nuclear accumulation of SHIP1 mutants derived from AML patients leads to increased proliferation of leukemic cells. Cellular Signalling, 2018, 49, 87-94.	1.7	7
32	Truncated O-GalNAc glycans impact on fundamental signaling pathways in pancreatic cancer. Glycobiology, 2021, , .	1.3	6
33	Combined Targeting of AKT and mTOR Inhibits Tumor Formation of EpCAM+ and CD90+ Human Hepatocellular Carcinoma Cells in an Orthotopic Mouse Model. Cancers, 2022, 14, 1882.	1.7	6
34	AKT1 and PTEN show the highest affinities among phosphoinositide binding proteins for the second messengers PtdIns(3,4,5)P3 and PtdIns(3,4)P2. Biochemical and Biophysical Research Communications, 2021, 568, 110-115.	1.0	5
35	Analysis of the FLVR motif of SHIP1 and its importance for the protein stability of SH2 containing signaling proteins. Cellular Signalling, 2019, 63, 109380.	1.7	4
36	Differential regulation of extracellular matrix proteins in three recurrent liver metastases of a single patient with colorectal cancer. Clinical and Experimental Metastasis, 2020, 37, 649-656.	1.7	4

#	Article	IF	Citations
37	Investigation of the function of the PI3-Kinase / AKT signaling pathway for leukemogenesis and therapy of acute childhood lymphoblastic leukemia (ALL). Cellular Signalling, 2022, 93, 110301.	1.7	4
38	Discontinuing MEK inhibitors in tumor cells with an acquired resistance increases migration and invasion. Cellular Signalling, 2015, 27, 2191-2200.	1.7	3
39	Characterization of the substrate specificity of the inositol 5-phosphatase SHIP1. Biochemical and Biophysical Research Communications, 2020, 524, 366-370.	1.0	3
40	Ectopic Expression of Hematopoietic SHIP1 in Human Colorectal Cancer. Biomedicines, 2020, 8, 215.	1.4	2
41	JAK2-V617F is a negative regulation factor of SHIP1 protein and thus influences the AKT signaling pathway in patients with Myeloproliferative neoplasm (MPN). International Journal of Biochemistry and Cell Biology, 2022, 149, 106229.	1.2	2
42	"Alcohol and nicotine"--Concept and evaluation of an interdisciplinary elective course with OSPE in preclinical medical education. GMS Zeitschrift FÃ¼r Medizinische Ausbildung, 2014, 31, Doc9.	1.2	0